JOAQUÍN
MARTÍNEZ LÓPEZ
Catedrático de universidad
Hospital del Mar
Barcelona, EspañaHospital del Mar -ko ikertzaileekin lankidetzan egindako argitalpenak (23)
2024
2023
-
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)
Leukemia
-
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
Leukemia, Vol. 37, Núm. 2, pp. 339-347
-
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
International Journal of Molecular Sciences, Vol. 24, Núm. 10
-
Role of light chain clearance in the recovery of renal function in multiple myeloma: another point of view
Clinical Kidney Journal, Vol. 16, Núm. 6, pp. 1014-1021
2021
2019
-
The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients
British Journal of Haematology, Vol. 186, Núm. 2, pp. 263-268
2018
-
Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia
British Journal of Haematology
-
Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis
Leukemia
-
Prognostic risk models for transplant decision-making in myelofibrosis
Annals of Hematology, Vol. 97, Núm. 5, pp. 813-820
2017
-
Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid
Annals of hematology, Vol. 96, Núm. 7, pp. 1069-1075
-
Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis
European Journal of Haematology, Vol. 98, Núm. 4, pp. 407-414
-
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
Haematologica, Vol. 102, Núm. 1, pp. 103-109
2016
-
Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method
Annals of Hematology, Vol. 95, Núm. 5, pp. 719-732
-
Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera
British Journal of Haematology, Vol. 172, Núm. 5, pp. 786-793
-
Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera
European Journal of Haematology, Vol. 96, Núm. 3, pp. 285-290
2014
-
Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis
Haematologica
-
The international prognostic scoring system does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis
Haematologica
-
Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation
Leukemia, Vol. 28, Núm. 6, pp. 1334-1340
2011
-
Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia
Annals of Hematology, Vol. 90, Núm. 8, pp. 939-946